PMID: 7541508Aug 1, 1995Paper

Use of granulocyte colony stimulating factor to reduce the toxicity of super-VAC chemotherapy in advanced solid tumours in childhood

Medical and Pediatric Oncology
C A JonesM M Stevens

Abstract

Children with advanced solid tumours at the Royal Alexandra Hospital for Children (RAHC) receive an intensive four drug chemotherapy combination, Super-VAC (cyclophosphamide, 500 mg/m2, adriamycin, 30 mg/m2, actinomycin-D, 0.5 mg/m2, all daily for 3 days, and vincristine, 1.5 mg/m2 weekly). The majority of patients respond well to three courses of such therapy, but with considerable morbidity, including fever, neutropenia, and mucositis. In an attempt to reduce the morbidity of Super-VAC, G-CSF was added. We documented various parameters in 12 patients who received 28 cycles with G-CSF and compared them to an historical control group of 37 cycles in the preceding 14 patients who received Super-VAC. The median duration of each cycle was 23 days with G-CSF and 28 days without G-CSF (P = 0.004). However, differences in requirements for inpatient care (median 16 v. 20 days), intravenous antibiotics (median 9 v. 10 days), amphotericin (median 5 v. 3 days), morphine (median 8.5 v. 7 days), or TPN (median 6.5 v. 8 days) did not reach statistical significance. As expected, a significant difference in neutrophil recovery was demonstrated between the two groups (median 11 v. 16 days, P < 0.0001) but not in platelet recovery (median 13 v....Continue Reading

References

Jan 1, 1975·Medical and Pediatric Oncology·J A OrtegaM R Karon
Nov 28, 1992·Lancet·G GüntherS Burdach
Jan 1, 1992·Medical and Pediatric Oncology. Supplement·J HolldackG Schulz
Apr 1, 1991·Pediatric Clinics of North America·S L BergF M Balis
Jun 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N V Cheung, G Heller
May 18, 1989·The New England Journal of Medicine·W P HammondD C Dale
Dec 1, 1973·Cancer·C P HoltonB E Favara
May 1, 1969·The Journal of Pediatrics·C B Pratt
Mar 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A D SeidmanY Tao

❮ Previous
Next ❯

Citations

Feb 14, 2002·British Journal of Haematology·Thomas Lehrnbecher, Karl Welte
Jun 16, 2006·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Inger von BültzingslöwenDorothy Keefe
Oct 13, 2021·Pediatric Blood & Cancer·Hannah JeterEmily Waite

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.